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Severe Plasmodium falciparum malaria is associated with hypoargin-
inemia, which contributes to impaired systemic and pulmonary nitric
oxide (NO) production and endothelial dysfunction. Since intravas-
cular hemolysis is an intrinsic feature of severe malaria, we investi-
gated whether and by which mechanisms free heme [Fe(III)-proto-
porphyrin IX (FP)] might contribute to the dysregulation of L-arginine
(L-Arg) metabolism and bioavailability. Carrier systems “y” [or
cationic amino acid transporter (CAT)] and “yL” transport L-Arg
into red blood cells (RBC), where it is hydrolyzed to ornithine and
urea by arginase (isoform I) or converted to NO· and citrulline by
endothelial nitric oxide synthase (eNOS). Our results show a signif-
icant and dose-dependent impairment of L-Arg transport into RBC
pretreated with FP, with a strong inhibition of the system carrier yL.
Despite the impaired L-Arg influx, higher amounts of L-Arg-derived
urea are produced by RBC preexposed to FP caused by activation of
RBC arginase I. This activation appeared not to be mediated by
oxidative modifications of the enzyme. We conclude that L-Arg
transport across RBC membrane is impaired and arginase-mediated
L-Arg consumption enhanced by free heme. This could contribute to
reduced NO production in severe malaria.
malaria; ferriprotoporphyrin IX; arginase
IN DISEASES with prominent intravascular hemolysis such as
malaria, thalassemia, and sickle-cell disease (SCD), the capac-
ity of the scavenging proteins haptoglobin and hemopexin
quickly becomes saturated and the subsequent increase in free
plasma ferric heme exerts toxic, proinflammatory, and prooxi-
dant effects adversely affecting endothelial function (37).
Heme also promotes the expression of adhesion molecules
(ICAM-1, VCAM, and E-selectin) on endothelium in vitro
(37). This could increase endothelial adhesion of parasitized
red blood cells (pRBC), which is a central feature of Plasmo-
dium falciparum malaria pathophysiology characterized by
sequestration and microvascular obstruction, with impaired
perfusion (9).
In addition, we (26) and others (6) have previously shown
that free heme can readily enter the RBC membrane, affecting
its structural and rheological properties including a decrease in
RBC deformability. The effects on the RBC are mediated by a
heme-induced reduction in cell volume, oxidative injury,
and/or phosphorylation of band 3 (24–26) and may contribute
to microvascular flow impairment in areas of intense seques-
tration where the lumen of the vessels is significantly reduced.
In addition, studies performed in African children with cerebral
malaria have demonstrated impaired production of nitric oxide
(NO·), whose deficiency might be also exacerbated by intra-
vascular hemolysis increasing cell free Hb, causing NO· deac-
tivation (1, 21). Beneficial effects of NO· include the mainte-
nance of normal platelet function through the downregulation
of aggregation and adhesion (31, 32) and a decrease in cyto-
kine production (10) and in cytoadherence of pRBC to the
microvascular endothelium (35). RBC possess nitric oxide
synthase (NOS) activity, and RBC NO· is involved in the
regulation of RBC deformability as well as in inhibition of
platelet aggregation (14, 15, 27, 30). RBC NOS shares the
common substrate L-arginine (L-Arg) with arginase I, present in
high concentration in erythrocytes and responsible for the
hydrolysis of L-Arg to urea and L-ornithine. Low levels of
plasma L-Arg are common in adults and children with severe
cerebral malaria, are directly correlated with disease severity,
and contribute to impaired NO· production and endothelial
dysfunction (18, 42). Different explanations for hypoarginine-
mia in malaria have been suggested, such as cytokine-induced
activation of arginase I and II (23), increase in plasma arginase
(33), inadequate arginine adsorption by enterocytes, or endog-
enous biosynthesis or recycling (18).
The aim of the present study was to investigate the role of
free heme in the dysregulation of arginine metabolism ob-
served in malaria and other hemolytic diseases. We show that
free heme compromises L-Arg transport into the RBC mainly
through inhibition of the carrier system “yL” and promotes
intracellular L-Arg degradation by activation of arginase I.
MATERIALS AND METHODS
Chemicals, blood, and reagents. Donor blood was kindly provided
by the Association of Voluntary Italian Blood donors (AVIS), the
national Italian nonprofit organization for blood donation. The ethical
committee of AVIS authorized the use of blood for this research
project with the informed consent of donors.
L-[2,3,4-3H]Arg (37 MBq/1 mCi) was from GE Healthcare Life
Sciences. Other biochemicals were purchased from Sigma (Sigma
Italia, Milan, Italy). Ferriprotoporphyrin IX (FP) and hematoporphy-
rin IX (HP) stock solutions were prepared daily by resuspension in
DMSO and dilution in PBS, and porphyrin equivalents were quanti-
fied by reading the absorbance at 385 nm or 396 nm, respectively (ε385
hematin  6.1  104 M/cm, ε396 HP  2.72  104 M/cm).
Microvascular endothelial cells (HMEC-1) were kindly provided by
Prof. Donatella Taramelli (Dipartimento di Sanita` Pubblica-Microbio-
logia-Virologia, University of Milano). Cells were maintained in
MCDB 131 medium (Invitrogen, Milan, Italy) supplemented with
10% fetal calf serum (HyClone), 10 ng/ml epidermal growth factor
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(Chemicon), 1 g/ml hydrocortisone, 2 mM glutamine, 100 U/ml
penicillin, 100 g/ml of streptomycin, and 20 mM HEPES buffer, pH
7.4 (EuroClone).
Preparation of RBC, cell-free extracts, and RBC membranes.
Citrate/phosphate/dextrose (CPD)-anticoagulated blood was obtained
from healthy A-positive donors and used within 5 days of withdrawal.
Aliquots of blood were centrifuged at 1,850 g and 4°C for 5 min, the
buffy coat was removed, and the erythrocyte pellet was washed three
times with 10 volumes of cold (4°C) PBS. RBC were gently resus-
pended at 10% hematocrit (Hct) with PBS-5 mM glucose (PBSG) and
used immediately after isolation. RBCs were exposed to FP for 60 min
at 37°C under continuous gentle shaking. Cells were then pelleted by
centrifugation at 1,850 g for 10 min, washed twice with PBSG, and
resuspended at 40% Hct in the same buffer but containing 5 mM
L-Arg. Suspensions of control or treated RBC were incubated at 37°C
for the indicated times, and arginase activity was assessed in either the
total suspension or the supernatant obtained by centrifugation (1,850
g, 5 min), in which the release of urea was also measured. Cell-free
extracts (total lysates) were obtained by hypotonic shock of RBC in 5
mM NaHPO4 buffer pH 8.0 (5P8 buffer) and three freeze-thawing
cycles. In some experiments, RBC cytosol and membranes were
prepared by centrifugation for 30 min at 20,000 g of total lysates of
control and FP-exposed RBCs. Membranes were extensively washed
in 20 volumes of 5P8 buffer containing 0.1 mM EDTA. A final wash
of the membranes was performed in the same buffer without EDTA.
RBC membranes (300–400 g protein/250 l) or cytosol (25 mg
Hb/250 l) was incubated with 5 mM L-Arg and used for the
determination of urea production.
Measurement of urea production and arginase activity. For urea
determination, an aliquot of sample (cell-free extract, cytosol, or
membranes) was diluted with half the volume of ice-cold 10%
perchloric acid. The mixture was centrifuged, and an aliquot of the
clear supernatant was added to 800 l of the acid mixture H2SO4-
H3PO4-H2O (1:3:7, vol/vol/vol). Urea was colorimetrically measured
at 540 nm after the addition of 50 l of 9% -isonitrosopropiophe-
none (dissolved in 100% ethanol) and heating at 100°C for 45 min (8)
and is reported per unit of Hb content.
For arginase determination an aliquot of the whole RBC suspension
was lysed in 20–40 volumes of distilled water and activated for 45
min at 50°C in 75 mM glycine-0.75 mM MnCl2 pH 9.5 (1:1, vol/vol)
(16). Arginase activity was measured as the quantity of urea formed
after initiation of the reaction by the addition of 0.25 M (final
concentration) L-Arg (pH 9.7), followed by a 30-min incubation at
37°C after which the reaction was stopped by adding the acid mixture.
Arginase activity was also measured in RBC lysates incubated with
FP or HP just before the addition of L-Arg and corrected for back-
ground values in a blank solution containing the same amount of FP
or HP. Specific activity of arginase measured in the total RBC
suspension, RBC supernatant, or RBC lysate was expressed as mi-
cromoles of urea produced per minute (U) per gram of Hb. The
activity of the membrane-bound arginase was expressed as U per
milligram of protein.
Km of arginase of control and FP-treated RBC was determined by
performing the enzyme assay in the presence of increasing concen-
trations of L-Arg (2–30 mM) and graphically evaluated with the
Eadie-Hofstee graph.
Effect of oxidative stress on arginase activity. The effect of molec-
ular oxygen and oxidative stress on arginase activity was investigated by
different approaches. RBC were pretreated with the prooxidant system
0.3 mM FeSO4-0.5 mM ascorbate (3 h, 37°C), with 40 M of the
porphyrin isoform devoid of iron (HP) (1 h, 37°C), or with the radical
scavengers 5 mM N-acetyl-L-cysteine (NAC) or 100 M sulfosalazine
(SZ) (30 min, 37°C) before exposure to FP. Alternatively, before expo-
sure to FP, Hb was “poisoned” and oxygen depleted by bubbling carbon
monoxide (CO) for 10 min into the RBC suspension. In this experiment
the formation of Hb-CO was verified by the analysis of the ultraviolet-
visible (UV/Vis) spectra confirming the shift of the maximum absorbance
of the RBC suspension from 414 nm to 420 nm (22).
Measurement of L-Arg influx into erythrocytes and HMEC-1 cells.
Aliquots of control and FP-treated RBC (10% Hct) were supple-
mented with 0.2 mM L-[3H]Arg and incubated at 37°C for 5 min for
measurement of the initial flux rate. After incubation RBC were
centrifuged (1,000 g, 3 min) and washed in cold PBSG. Packed cells
were lysed with 2 volumes of 10% Triton X-100, and proteins were
precipitated with 3 volumes of 10% (vol/vol) trichloroacetic acid,
followed by -scintillation counting. The two saturable transport
systems were investigated separately by performing the incubation in
the presence of 2 mM N-ethylmaleimide (NEM) to inhibit the carrier
system y or in the presence of 1 mM leucine to inhibit the carrier
system yL (3).
HMEC-1 were seeded in quadruplicate at 1.5 105/well in MCDB
131 medium in 24-well flat-bottom tissue culture clusters (Costar,
3596) and pretreated for 60 min with FP (10–40 M). At the end,
cells were washed twice in PBSG and incubated for 5 min with 0.2
mM L-[3H]Arg in MCDB 131 medium. Cells were then washed twice
in PBS and resuspended in 1 N NaOH before -scintillation counting.
MetHb determination. The concentration of MetHb was estimated
from visible spectra of RBC hemolysate with the algorithm of Win-
terbourn (38), based on the measurement of optical densities at 560,
577, and 630 nm.
Statistical analysis. Results are reported as means with SD of at
least four experiments run in three to five replicates, unless otherwise
specified. Deviations from normal distribution were checked with the
Shapiro-Wilk and Shapiro-Francia tests for normality. Comparisons
between control and treated samples were made with a paired Stu-
dent’s t-test. For data that were not normally distributed and for
comparisons in which the SD between the groups was not approxi-
mately equal, the Wilcoxon matched-pairs signed-ranks test was used.
A test for trend across ordered groups was used to show dose response
of arginine uptake to FP.
RESULTS
Activity of arginase in RBC pretreated with FP. The con-
centration of FP chosen for the experiments was kept below 40
M to avoid hemolytic destruction of RBC above 2–3%. RBC
pretreated for 60 min with 40 M FP showed a mean increase
in arginase activity of 20% (Table 1). Results reported in
Table 1 refer to the arginase activities measured after 16-h
incubation in relation to the Hb concentration measured at the
end of the incubation. Although the reported results are after
16-h incubation, measurements just after the start of the incu-
bation, and as a function of the length of incubation up to 16 h,
showed that the FP-mediated increase in arginase activity was
immediate and that the extent of activation was independent
from the incubation time (data not shown). As shown in Table
1, the measured FP-mediated arginase activation was the same
in the complete RBC suspension compared with the extracel-
lular medium. The radical scavengers NAC and SZ did not
prevent the increase of arginase activity induced by FP. How-
ever, pretreatment of RBC with the prooxidant system FeSO4-
ascorbate caused a mean increase of arginase activity of 10%.
HP, the porphyrin analog devoid of iron, enhanced the arginase
activity to the same extent as FP, strongly suggesting that
heme-iron-mediated oxidative reactions are not involved.
As shown by the broad UV/Vis spectrum, FP is largely present
in aqueous solutions as dimers and aggregates due to the forma-
tion of -oxo linkages among iron atoms of the ferri heme units
(4). L-Arg, at the same concentrations and pH used in the arginase
assay, was found to change the UV/Vis spectrum of FP, causing
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a shift of the absorbance at 400 nm (Fig. 1A). This indicates the
ability of L-Arg to interact with the FP -oxo dimers and aggre-
gates, possibly through inducing the formation of FP monomers
and/or adducts of L-Arg-FP. In agreement with the recent paper by
Coghi et al. (7), in which it is shown that heme solubilized by an
excess of L-Arg maintains the capability of inducing iron-medi-
ated oxidative reactions, we hypothesize that L-Arg and FP do not
associate via the heme iron but through the interaction between
the carboxylate and guanidine groups. We speculate also that the
interaction of L-Arg with HP is identical to that with FP. However,
HP in solution is predominantly nonaggregated (monomers), as
shown by the sharp UV/Vis spectrum centered around 400 nm,
and the L-Arg-induced shift of the UV/Vis spectrum of HP is less
prominent (Fig. 1B).
The interaction of L-Arg with FP was also demonstrated at
pH 7.4 (not shown), appeared to be specific for L-Arg (Fig.
1C), and could explain the increase of the apparent Km value of
arginase in FP-treated RBC (5.37 	 0.9 mM vs. 3.96 	 0.8
mM in control RBC, P 
 0.05) (Fig. 2).
Measurement of urea production in control and FP-pre-
treated RBC. Urea production was used as an index for changes
in arginase activity following incubation with L-Arg and was
measured in total RBC lysates, cytosol, or RBC membranes
prepared from control or FP-treated RBC. Figure 3A shows that
urea produced by total lysates from FP-RBC after incubation
with increasing concentrations of L-Arg was significantly
higher compared with controls. Interestingly, an enhanced
production of urea in FP-RBC was observed when the assay
was performed in the cytosol fraction, whereas no differences
were shown when L-Arg was incubated with RBC membranes,
representing only membrane-bound arginase (Fig. 3B).
Urea production in intact RBC pretreated with FP and
measured in the extracellular medium after 16-h incubation
was increased by FP in a dose-dependent way (Fig. 4A). The
Table 1. Total and extracellular arginase activity of human red blood cells in presence of heme products or pro- and
antioxidant systems
Fraction Treatment n
Arginase Activity (U/g Hb)
in Controls
Arginase Activity (U/g Hb)
After Treatment Difference [mean (95% CI)] P Value
Total FP (40 M) 12 57.6	 15.0 69.5	 15.8 11.8 (8.0–15.7) 
0.001
FP (40 M) with NAC (5 mM) 5 56.8 	 8.3 72.0	 10 15.2 (9.0–21.5) 0.003
FP (40 M) with SZ (100 ) 70.5 	 8.0 13.8 (9.3–18.2) 0.001
Fe (0.3 mM)-ascorbate (05 mM) 63.3 	 3.4 6.5 (0.1–12.9) 0.048
HP (40 M) 8 55.5	 2.3 71.4	 1.7 15.9 (13.3–18.5) 
0.001
Supernatant FP (40 M) 6 55.0	 12.0 72.2	 15.0 17.3 (4.6–30.1) 0.018
Arginine activity values [in m urea produced/min (U)/g Hb] are means 	 SD for n samples. Human red blood cells (RBC) [0% hematocrit (Hct)] were
pretreated with Fe(III)-protoporphyrin IX (FP) or hematoporphyrin IX (HP) for 1 h at 37°C or Fe-ascorbate for 3 h at 37°C. After this, RBC were washed twice
in PBS-glucose and resuspended at 40% Hct in the same buffer. Arginase activity was assayed in the total suspension or the extracellular medium after 16-h
incubation. In a subset, RBC suspensions were exposed for 30 min at 37°C to 5 mM N-acetyl-L-cysteine (NAC) or 100 M sulfosalazine (SZ) before treatment
with FP. Arginase activity was compared in treated samples vs. controls by paired Student’s t-test. CI, confidence interval.
Fig. 1. A and C: Ultraviolet-visible (UV/Vis)
spectra of 10 mM ferriprotoporphyrin IX (FP)
alone (solid line) and in the presence of 250 mM
L-arginine (L-Arg) (dashed line; A) or 250 mM
L-lysine (L-Lys) (dashed line; C). B: UV/Vis
spectra of 10 mM hematoporphyrin IX (HP)
alone (solid line) and in the presence of 250 mM
L-Arg (dashed line). Abs, absorbance.
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higher urea concentrations (expressed as mM values) measured
in the extracellular medium could partly be explained by the
presence of FP-induced hemolysis (2–2.5% in FP RBC vs.
0.8–1% in controls), which causes the release of intracellular
arginase. However, differences between control and FP-treated
RBC remained significant when the urea levels were expressed
as nanomoles per milligram of Hb, which corrects for the
degree of hemolysis [mean (SD): 148% (10) absolute increase
at 40 M FP before correction vs. 132% (5) increase after
correction]. In contrast with the change in arginase activity, the
activity of lactate dehydrogenase referred to the Hb content of
the supernatants was identical in control and FP-treated RBC
(not shown). The effects of oxidative stress on urea production
are shown in Fig. 4B. Pretreatment of RBC with the prooxidant
system Fe-ascorbate caused a significant increase of urea
released in the extracellular medium. To evaluate whether the
FP-related increase in urea depends on its oxidative properties,
we studied urea production in RBC incubated with HP, which
is depleted of the iron II/iron III redox cycling of porphyrin.
Urea production remained similarly increased in this system,
suggesting that FP-induced oxidative stress is not required for
FP-induced activation of the enzyme. Also, in CO-treated RBC
urea production was significantly higher in RBC incubated
with FP. In these RBC, CO binding to heme-iron completely
prevented the dose- and time-dependent formation of MetHb
induced by FP (not shown).
Arginine influx. In addition to free, nonsaturable diffusion,
L-Arg influx into RBC is supported by the carrier systems y
Fig. 2. Eadie-Hofstee graph for arginase activity of control (C) and 40 M
FP-pretreated (FP) red blood cells (RBC). Each data point represents a
triplicate sample of 4 separate experiments. V0, initial velocity.
Fig. 3. A: urea production in total lysates of control RBC or RBC pretreated
with 40 M FP (60 min, 37°C). Incubation was performed for 16 h at 37°C in
the presence of increasing concentrations of L-Arg (0.1–5 mM). This is a
representative experiment out of 5, made in triplicate. B: mean urea values
from 5 paired lysates, cytosols, and ghosts prepared from control and FP
samples (40 M FP, 60 min, 37°C). Incubation was performed for 16 h at 37°C
in the presence of 5 mM L-Arg. Paired comparisons were made by Student’s
t-test.
Fig. 4. A: urea released in the extracellular medium by control RBC or RBC
pretreated for 60 min with increasing concentrations of FP and then incubated
for 16 h at 37°C in the presence of 5 mM L-Arg. Results are expressed as
absolute values (mM) or per milligram of Hb. Results are means 	 SD of 4
experiments. *P 
 0.01 vs. control. B: urea released in the extracellular
medium (n  5 experiments) by control RBC, RBC pretreated for 60 min with
40 M FP or HP, or RBC pretreated for 3 hrs with Feascorbate (Fe-Asc,
0.3–0.5 mM). CO-FP indicates that the RBC suspension was exposed for 10
min to a carbon monoxide atmosphere before treatment with 40 M FP. Bars
represent means and 95% confidence intervals (CI). Comparison over all
groups: P 
 0.001 (4 df); paired comparisons with control: *P  0.04 by
Wilcoxon signed-rank test.
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(or CAT) and yL (3, 20). Kinetics of L-Arg influx were
determined under conditions allowing us to assess the individ-
ual contributions of systems y and yL, by selective inhi-
bition of the systems by NEM and leucine, respectively (3).
Figure 5 shows that FP impairs the total L-Arg influx in a
dose-dependent manner (Fig. 5A). The rate of L-Arg uptake by
RBC treated with 40 M FP is reduced by 40% independent
of the incubation time (Fig. 5B). From the values reported in
Fig. 6A corrected for the diffusion component, it was calcu-
lated that contribution of systems y and yL to the total
transport was about 68% and 17%, respectively, in control
RBC and 72% and 7% in FP-RBC. Impairment of yL
transport by FP was compensated by a higher percentage of
L-Arg free diffusion (22% in FP RBC vs. 15% in control RBC).
By comparing the absolute amount of L-Arg influx (cpm
[3H]arginine/107 RBC), it can be calculated that in FP-RBC
y and yL transports were reduced by 30% and 73%,
respectively, with no changes in the free diffusion. Preliminary
experiments in our laboratory showed that pretreatment with
FP also causes a dose-dependent impairment of the total L-Arg
influx into endothelial cells (HMEC), with a maximum of 30%
inhibition at a FP concentration of 40 M (data not shown).
DISCUSSION
Erythrocytes represent an important compartment for argi-
nine metabolism, because arginine can be hydrolyzed to orni-
thine and urea by arginase (isoform I) or converted to NO· and
citrulline by a functional endothelial NOS (eNOS) activity
(15). Among its many other functions, NO· is pivotal for proper
endothelial function, and hypoargininemia and reduced NO
availability have been implemented in the pathophysiology of
severe malaria (42). Under conditions of low L-Arg concentra-
tions NOS is uncoupled, producing reactive oxygen species
instead of NO (41). Also, since L-Arg is essential for both
proliferation and differentiation of erythroid cells (36), inhibi-
tion of L-Arg influx by FP may have critical consequences for
the hematopoiesis processes already impaired by proinflamma-
tory cytokines and hemozoin (5). Impaired NO· production
could enhance the rigidifying effects on RBC mediated by
FP-induced band 3 phosphorylation (2, 25, 29). Elevated argi-
nase activity has been reported in both plasma and RBC lysate
in SCD, a hemoglobinopathy sharing some important patho-
physiological features with P. falciparum malaria (11, 21).
However, while the elevated activity in plasma can be easily
accounted for by RBC lysis during intravascular hemolysis, the
possibility that arginase in the intra- or extracellular compart-
ment may be directly activated by heme has not been investi-
gated. Arginase activity is enhanced in vitro by hydroxyl
radicals produced by the Fenton reaction (12) and is dimin-
ished in human RBC after consumption of flavanol-rich bev-
Fig. 5. A: total influx of L-[3H]Arg (200 M) in control RBC or RBC
pretreated with increasing concentrations of FP. Influx of L-Arg was deter-
mined over 5-min incubation. Bars represent mean (5 experiments) and 95% CI.
Test for trend: P 
 0.001. B: time course of total L-[3H]Arg (200 M) influx in
control RBC or RBC pretreated with 40 M FP. Results are means 	 SD of 4
experiments.
Fig. 6. A: L-[3H]Arg uptake into control RBC or RBC pretreated with 40 M
FP (n  4 experiments/treatment). Rates were measured in the absence (no
addition) or the presence of either 1 mM unlabeled leucine (Leu) or 2 mM
N-ethylmaleimide (NEM). Boxes indicate medians and interquartile ranges. Bars
represent upper and lower adjacent values. P 0.068 for each paired comparison
between treatment and control by Wilcoxon signed-rank test. B: contribution of
transport systems yL and y and free diffusion to the total L-[3H]Arg transport
in control RBC or RBC pretreated with 40 M FP.
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erages (34). Indeed, in agreement with the above findings, we
could show an increase in arginase activity in RBC pretreated
with the prooxidant system FeSO4-ascorbate. Although the
precise mechanisms of these effects have not been clarified,
our hypothesis is that FP might enhance arginase activity of
RBC through oxidative modifications, resulting in reduced NO
synthesis and/or availability. However, it appeared that FP is
able to enhance arginase activity in an oxidative-independent
way. RBC pretreated with HP (the porphyrin analog devoid of
the oxidative iron) showed an increase in urea production
similar to that of FP-treated RBC, indicating that oxidative
stress cannot explain the increase of enzymatic activity induced
by FP and suggesting a direct effect of the porphyrin on the
enzyme. This is also supported by the finding that enhanced
arginase activity induced by FP can neither be prevented nor
reduced by the radical scavengers NAC and SZ or by Hb
saturated with CO. CO binds to iron heme, preventing it from
participating in redox cycling as illustrated by the prevention of
FP-induced formation of MetHb. This potentially antioxidant
mechanism of CO limiting superoxide-dependent Fenton reac-
tions has recently been proposed as a mechanism for the
protective effect of CO in murine cerebral malaria (28).
The reported arginase activities and Km in control RBC were
in agreement with other authors (11, 39) and were both in-
creased by FP. The capability of L-Arg to interact with FP
(shown by the shift of the UV/Vis spectra) and inducing the
formation of FP monomers and/or adducts of L-Arg-FP sug-
gests a different interaction between arginase and L-Arg being
responsible for these modifications. A similar interaction can
be hypothesized between HP and L-Arg, even though the
L-Arg-induced shift of the UV/Vis spectrum of HP is less
prominent since here HP is already mainly present as a mono-
mer. The increase in arginase activity was similar in the total
RBC suspension compared with the extracellular medium and
confirmed by the accumulation of urea, which can move freely
across the RBC membrane.
In addition to increased arginase activity, intracellular NO
production could also be compromised by reduced transmem-
brane transport of L-Arg into the RBC. We could show that FP
inhibits y and yL transmembrane transports of L-Arg by
30% and 73%, respectively, with no changes in the free
diffusion of L-Arg.
In agreement with published data, the relative contribution
of transport system y to the L-Arg transport in control RBC
was68% (3). Impairment of system y observed in FP-RBC
was not unexpected because of its known sensitivity to the
sulfydryl reagent NEM and the reactivity of FP with sulfydryl
groups (26). The mechanisms underlying the inhibition of
system yL by FP need further investigation.
FP-induced hemolysis was a potential confounder in our
experiments. Arginase and Hb are both released from RBC as
they undergo lysis. However, after correction for the Hb
content of the sample, the arginase activity in the extracellular
medium remained significantly increased. This implies that the
increase in enzyme activity was exclusively resulting from the
effects of porphyrin on the protein.
It has been demonstrated that the activity of RBC arginase is
enhanced after binding to the membrane through membrane
protein flotillin-1 (13). Interestingly, we did not find any
difference in the production of urea when L-Arg was incubated
with RBC membranes prepared from control and FP-treated
RBC. This observation excludes the possibility that transloca-
tion to the membrane might be the responsible molecular
mechanism for FP-induced activation of RBC arginase. The
enhanced production of urea induced by FP was observed only
in the total and the cytosolic fraction of RBC and can therefore
only be attributed to the soluble fraction of enzyme.
Our findings show that free heme can significantly impair
L-Arg uptake through CAT and enhances L-Arg consumption
through RBC arginase depleting the L-Arg pool as a source for
NO· production. The rate of L-Arg uptake and degradation by
arginase may limit the rate of NO synthesis by FP-treated
RBC. Release of a more active arginase by FP-destabilized
RBC during intravascular hemolysis could also contribute to
and worsen hypoargininemia, reducing L-Arg availability for
NO synthesis in endothelial cells. In addition, the released
heme could further impair transport of L-Arg into endothelial
cells, because we showed that FP has this effect on L-Arg
transport into HMEC in vitro. This finding was not unexpected
since the same cation amino acid system y is responsible for
most of the transmembranous L-Arg transport in these cells
(39, 40). Further investigations are needed to quantify the
effects of FP on endothelial y and yL Arg transporters.
Although intracellular L-Arg concentrations greatly exceed the
very low Km of NOS (micromolar range), dependence of eNOS
activity from the arginine availability has been observed in
endothelial cells and called the “arginine paradox” (17). The
arginine paradox has been explained by the physical associa-
tion of L-Arg transporters and eNOS in caveolar complexes
providing a mechanism for direct channeling of extracellular
L-Arg for NO· synthesis (19).
In conclusion, we have shown that free heme impairs L-Arg
transport across the RBC membrane and increases intra- and
extraerythrocytic arginine breakdown. These mechanisms can
contribute to the observed reduced NO· production in severe
malaria, which has several important pathophysiological im-
plications.
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